Surgical Innovations Share Discussion Threads

[zipstuck] 11/9/2018 07:51

Of more interest will be H1 next year with the possibility of USA new product approvals and Cellus back on track and all areas up to speed.

[jmf69] 11/9/2018 07:44

Expecting to see full year revenue in excess of 11m GBP

[jmf69] 11/9/2018 07:43

Results are as expected and the outlook is good especially with the application for USA approval of the yelloport elite range.Ams results tomorrow should give an indication of how successful the new improved liquiband fix8 will be. Also nice to see an uptick in precision engineering.Gla

[bashor] 10/9/2018 16:41

Good luck to all those that are in for tomorrow, as long as the trading statement has wording missing such as unfortunately, impace, delayed I’m sure we will be just fine, back after reading the 7am RNS

[john148] 10/9/2018 13:02

I believe news will be good and upbeat. My forecast 4.35- 4.50 run up to Xmas.

[jmf69] 10/9/2018 11:43

Here's one https://www.linkedin.com/feed/update/urn:li:activity:6438006647595036672

[buywell3] 10/9/2018 11:38

IMO the update will be positive re 2nd half Meccellis sales in particular as I have recently posted.

I also think we are likely to hear some further news re using more Distributors in the USA and other countries to sell SUN products.

What has not been discussed is the ''exciting and innovative new products which are due for launch in the UK market during 2019''

refered to in the last RNS extract below

''Elemental and Meccellis have entered into an extended agreement providing Elemental with exclusive UK distribution rights in respect of the CELLIS range for a period of three years expiring in June 2021, with a subsequent automatic renewal period of two years, subject to meeting minimum purchase obligations. This agreement, and the new CE mark, cover some exciting and innovative new products which are due for launch in the UK market during 2019.''

I might be wrong but I am thinking that these could well be used for the NEW applications that AMS will be using the SUN Liquiband Fix8 divice for in addition to the USA FDA approval they are currently seeking for it.

Either way at long last IMO we are due for a few more positive RNS's for a change

Recent sub 3p SUN share price chartwise I hope is now behind it and those enterprising souls that loaded up at Sub 3p could now be rewarded for their bravery.

[gbh2] 10/9/2018 10:18

Good Luck to you stalwarts :)

[bashor] 10/9/2018 10:06

Agreed it’s all about the forward looking statement

[jmf69] 10/9/2018 09:54

I don't expect the results tomorrow to be particularly good as we know revenue in the region of 5m GBP. It's the outlook and trading update I'm hoping will be providing further upside.

[bashor] 10/9/2018 09:27

slowly slowly catchy monkey

[bashor] 07/9/2018 10:49

Steady away no sudden spikes please

[buywell3] 06/9/2018 12:40

From what has been said , the Elemental Healthcare team of SUN are now in the process of sorting out advance Meccellis orders from clients so that they will be ready to be shipped off '' within four to eight weeks'' as per the RNS announcement.

Thus this statement from may 25th

''This has the effect of reducing revenue expectations for the current financial year by approximately 10%, or £1.25m, on the cautious assumption that sales do not resume in the current year. ''


Looks set to be updated next week

I think a reasonable take is that circa 3 to 4 months worth of Meccellis product could now be sold in the remaining year

IMO this could equate to an additional add to turnover of £0.6M

Which will make the SUN market a bit happier I would have thought

[jmf69] 05/9/2018 16:00

Thought this would have bounced back further after the Cellis ce approval update

[bashor] 05/9/2018 11:37

Well I’m going for 3.6p anymore for anymore

[jmf69] 05/9/2018 10:08

That will depend on how good the trading update is and guidance for the rest of the year

[bashor] 05/9/2018 09:33

Predictions for the closing share price Tuesday

[buywell3] 31/8/2018 09:51

Surgical Innovations Group PLC CE mark validation indicated for CELLIS range
29/08/2018

''Formal certification is anticipated within four to eight weeks, during which period Group management are working closely with Meccellis to optimise inventory logistics for the UK market. The Elemental sales team will engage with UK customers during this time to facilitate orderly replenishment of CELLIS products once availability information becomes clear.''

[buywell3] 31/8/2018 09:49

''This has the effect of reducing revenue expectations for the current financial year by approximately 10%, or £1.25m, on the cautious assumption that sales do not resume in the current year. ''


25 May 2018

Trading Update

The Company is experiencing delays in the supply of products for its UK distribution business, Elemental Healthcare Limited ("Elemental"), sourced from Meccellis Biotech SA ("Meccellis").

Meccellis began to undertake a transition to a new notified body for European regulatory approval,including the recertification of its existing products, and the certification of new products.

This transition has encountered delays which were not anticipated until very late in the process

It is apparent that product availability will have a continuing impact on revenues of SI Group in the current financial year. The SI Board has determined that it would be prudent to exclude revenues from Cellis products from current year expectations until such time as there is certainty regarding the availability of
current and new products in this range following regulatory approval.

This has the effect of reducing revenue expectations for the current financial year by approximately 10%, or £1.25m, on the cautious assumption that sales do not resume in the current year.

[bashor] 31/8/2018 07:26

But how will the restocking impact on the bottom line in terms of % margins

[bjfanc] 30/8/2018 22:07

No reason, why it shouldn't trade back above 3.5p. If they can confirm, expectations regarding the restocking of supplies.

[meijiman] 30/8/2018 18:10

Aint no shortage of fatties roaming the streets...should be good for business.

[bashor] 30/8/2018 17:41

I think that given we now know there is a trading statement to accompany the results on the 11th we have a very good chance that’s it’s going to be very positive given the earlier up beat article earlier in the year.... sitting tight

(Sharecast News) - Designer, manufacturer and distributor of innovative medical technology, Surgical Innovations Group, said on Tuesday that total group revenues for the six months ending 30 June were expected to exceed £5m.

The AIM-traded firm told shareholders at its annual general meeting that profitability was also expected to be "slightly ahead" of the corresponding period last year, with it also anticipating "much stronger results" in the second half of the year.

Executive chairman Nigel Rogers said export sales of SI branded products were gaining increasing traction in many overseas markets, as a result of product range extensions, additional sales resources and business development initiatives.

"We anticipate further opportunities to improve our market share across several key geographical markets to be delivered in the coming months," he told the meeting.

"Market conditions in the UK during the first half of the year have been challenging as a result of reduced activity levels of elective surgery in the NHS, and the supply chain disruption in respect of the Cellis range of biological matrices."

Rogers said there were positive signs that NHS hospitals were continuing to return to normalised activity levels, with recent government policy announcements regarding a longer-term funding settlement for the NHS described as "encouraging".

"Distribution sales in the UK market will also benefit from additional product lines taken on during the first half of the year, and the renewal of a number of key contracts.

"Revenues from OEM customers have been steady, and are expected to increase in the second half of the year, following the redesign of certain key products and additional revenues from precision engineering products."

Rogers said the company's management had used the period of subdued demand to bear down further on working capital, delivering "significant reductions" in inventory levels and strong cash flow.

"The group is expected to have little or no net debt at 30 June."

Surgical Innovations said its interim results for the first half of the year would be released in September